by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
Treatments for ET and PV Moving Towards Disease Modification
by Christina T. Loguidice, OncLive Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia (ET) […]
Has PV become a disease of the middle-aged?
by David Wallace Dr. Ghaith Abu-Zeinah, Assistant Professor at Weill Cornell Medical College, Silver MPN Center is our MPN specialist answering this important question. David Wallace, PV Reporter, is your host and patient advocate. TRANSCRIPT | Has PV become a disease of the middle-aged? David: For many years PV been considered an older person’s disease. […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]